Severe Optic Neuropathy Induced by Very Prolonged Tedizolid as Suppressive Therapy: Description of a Case Report and Implication for Better Assessment

F Coustilleres; E M Thillard; R K Khanna; S Olivereau; M Ouaissi; N Pansu; M L Le Lez

doi:10.1093/ofid/ofae517

Severe Optic Neuropathy Induced by Very Prolonged Tedizolid as Suppressive Therapy: Description of a Case Report and Implication for Better Assessment

Open Forum Infect Dis. 2024 Sep 24;11(9):ofae517. doi: 10.1093/ofid/ofae517. eCollection 2024 Sep.

Authors

F Coustilleres^{1

2}, E M Thillard³, R K Khanna^{4

5}, S Olivereau⁶, M Ouaissi⁷, N Pansu⁸, M L Le Lez⁴

Affiliations

¹ Department of Infectious Diseases, Tours University Hospital, TOURS, France.
² Infectious Diseases Mobile Team, Blois Simone Veil Hospital, BLOIS, France.
³ Pharmacovigilance Regional Center of Centre Val de Loire, Tours University Hospital, TOURS, France.
⁴ Department of Ophthalmology, Tours University Hospital, TOURS, France.
⁵ Faculty of Medicine, INSERM UMR 1253, iBraiN, TOURS, France.
⁶ Paliative Care Mobile Team, Tours University Hospital, TOURS, France.
⁷ Department of Visceral Surgery, Tours University Hospital, CHAMBRAY-LES-TOURS, France.
⁸ Department of Infectious Diseases, Montpellier University Hospital, MONTPELLIER, France.

Abstract

The long-term tolerability of linezolid is low because of mitochondrial toxicity, whereas tedizolid may represent a better option for suppressive therapy. We report a first presumed case of tedizolid-associated optic neuropathy after a very prolonged (18-month) intake and believe that screening for optic neuropathy should be considered for patients undergoing tedizolid suppression.

Keywords: optic neuropathy; oxazolidinones; suppressive therapy; tedizolid; vascular graft infections.

Publication types

Case Reports